Background: Controversy exists as to whether atrial fibrillation (AF) ablation guided solely by complex fractionated atrial electrogram (CFAE) has a good outcome despite not requiring pulmonary vein isolation (PVI). Objectives: The purpose of this study was to evaluate the effectiveness of AF ablation guided solely by targeting CFAE areas, and to determine whether its clinical efficacy has any relationship with unintentionally isolating the PV. Methods: We studied 100 consecutive patients (ages 59 ± 11 years; 54 with paroxysmal, 35 persistent, and 11 long-standing persistent AF), who underwent CFAE-ablation. PV potential (PVP) was recorded before and after ablation. After excluding 39 patients in whom sinus rhythm could not be maintained before ablation by internal cardioversion and/or who had a history of PVI(s), PVPs were analyzed. Results: AF was terminated during ablation in 98% of paroxysmal, 80% of persistent, and 55% of long-standing persistent AF patients. Nifekalant (0.3-0.6 mg/kg) was administered in 30%, 57%, and 83%, respectively. The common areas of CFAE around the PVs were anterior to the right PVs, posterior to the left PVs, and at the ridge of the left atrial appendage. Among Unintentional PV isolation by CFAE ablation 279 215 PVs in 61 patients (42 paroxysmal, 19 persistent), only 17 PVs (8%) were unintentionally isolated. The atrial potential to PVP was prolonged (>30 ms) in 13% of PVs. After at least 12 months of follow-up (23 ± 5 months), 65% of paroxysmal (11% with drug), 54% of persistent (37% with drug), and 45% of long-standing (60% with drug) AF patients were free from atrial arrhythmia after one session. Conclusions: CFAE-ablation terminates AF without isolating PVs in a high percentage of patients, and yields excellent clinical outcomes.
Introduction
Catheter ablation is an effective approach for the management of patients with atrial fibrillation (AF) [1] [2] [3] [4] [5] [6] [7] . Pulmonary vein isolation (PVI) is one of the most common strategies for ablation of paroxysmal AF, but the outcome of PVI alone for patients with persistent AF is poor [8] [9] [10] . Additional approaches, such as linear ablation after PVI have been reported [11] [12] [13] [14] [15] .
Nademanee et al. recently described a different approach for AF ablation. This strategy involved identifying the target ''substrate'' sites using electroanatomic mapping of complex fractionated atrial electrograms (CFAEs) [7, 16, 17] . Although PVI was not required with this approach, AF ablation guided solely by CFAE resulted in a high rate of success in maintaining sinus rhythm (SR) in patients with either paroxysmal or persistent AF. However, results of the study by Nademanee et al. were not replicated by others [6, 18, 19] . Thus, the role of CFAE-ablation in treating AF patients remains controversial.
Whether CFAE areas act as an AF substrate is also a subject of debate. Although some studies have reported that areas of CFAE act as an AF substrate [7, 14] and represent local micro-reentrant circuits acting as focal drivers of AF [20, 21] , other studies have shown that CFAEs are caused by increased autonomic nerve stimulation from epicardial ganglionic plexi that innervate the atrium and PVs and, in turn, trigger and/or maintain AF [22] [23] [24] [25] .
Despite these data, it is unclear what proportion of patients with AF can be terminated with this approach in clinical practice, and whether unintentional PVI can occur during CFAE-ablation. Thus, we conducted this study to evaluate how CFAE-guided ablation as the sole strategy for AF ablation affects the rate of AF termination, and to determine the long-term outcomes. Additionally, our goal was to determine and characterize PV potential (PVP) before and after AF ablation guided by CFAE, and to determine its relationship between the clinical outcomes and PVI.
Methods

Study population and protocol
This study comprised 100 consecutive patients (18 women and 82 men; mean age, 59 ± 11 years), including 54 (54%) patients with paroxysmal AF, 35 (35%) patients with persistent AF, and 11 (11%) patients with long-standing persistent AF with symptomatic drug refractory AF, who successfully underwent CFAE-ablation from September 2008 to January 2010, at Kagoshima University in Kagoshima, Japan.
Fourteen patients had a history of PVI. The patient characteristics are shown in Table 1 .
All antiarrhythmic drugs were discontinued at least 5 half-lives before the study, with the exception of amiodarone, which was discontinued at least 3 months before the study. All patients provided written informed consent for the procedure. The study protocol was approved by the institutional ethics committee. AF was defined in accordance with the 2007 Heart Rhythm Society Expert Consensus Statement [26] . Paroxysmal AF was defined as recurrent AF (≥2 episodes) that terminates spontaneously within 7 days. Persistent AF was defined as AF that is sustained for more than 7 days or as AF lasting less than 7 days, but necessitating pharmacologic or electrical cardioversion. And AF lasting more than 1 year was defined as long-standing persistent AF.
We excluded patients who were absent of PVP in all 4 veins due to previous PVI(s). We also excluded patients who could not be maintained in SR before ablation by a cardioversion due to difficulty recording PVP before ablation.
Mapping and ablation of AF
The following AF ablation technique, described by Nademanee et al. [7, 16, 17] was utilized for this study. Initially, an 8-mm NaviStar catheter (Biosense Webster, Inc., Diamond Bar, CA, USA) was used until April 2009, when we switched to a 3.5-mm NaviStar ThermoCool catheter (Biosense Webster) that became available in Japan. In brief, after coronary sinus (CS) was cannulated by decapolar catheter (Inquiry Luma-Cath, St. Jude Medical, Irvine, CA, USA) for recording and induction, patients underwent non-fluoroscopic electroanatomic mapping with the CARTO mapping system (Biosense Webster) at least 5 half-lives after cessation of antiarrhythmic drugs or at least 3 months after cessation of amiodarone. Heparin (3000 IU initial bolus, 1000-2000 IU subsequent boluses as needed to keep the activated clotting time >250 s) was administered for anticoagulation. All electroanatomic maps were created for patients who were in AF, either occurring spontaneously or by induction. Burst pacing utilizing a CS catheter to a lower limit of 1:1 capture or up to 150 ms was used to induce AF occasionally with a 0.01-0.02 g/kg/min isoproterenol infusion. When AF was terminated during the ablation procedure in paroxysmal AF patients, AF was re-induced until it was no longer inducible, because paroxysmal AF could be terminated spontaneously.
An electroanatomical map was created and displayed as a voltage map, and the areas of CFAE were identified manually, tagged, and associated with the atrial anatomy created by CARTO. This enabled the operator to associate areas of CFAE with the left atrium (LA), CS, and occasionally the right atrium, thereby identifying target sites for ablation.
Bipolar recordings were filtered at 30-500 Hz, and the CFAE was defined as follows: (1) fractionated electrograms composed of 2 or more deflections and/or a perturbation of the baseline with continuous deflection of a prolonged activation complex; and (2) atrial electrograms with a very short cycle length (≤120 ms).
After acquiring the voltage map associated with CFAE, we searched the areas of CFAE referring to the tagged points because CFAE areas have temporal spatial stability. Radiofrequency (RF) applications were delivered with a maximal power of 35 W with irrigation rates of 17-30 ml/min (3.5-mm NaviStar ThermoCool catheters). The power was reduced to 15-25 W in the posterior LA, or in the CS. An 8mm NaviStar catheter with a maximal temperature of 55 • C at the catheter tip and a maximal power of 50 W was used until it was replaced by a NaviStar ThermoCool catheter in April 2009.
The primary endpoints during RF ablation were either complete elimination of areas of CFAE or conversion of AF to SR with or without injection of nifekalant (0.3-0.6 mg/kg intravenously over 10 min), a Class III antiarrhythmic drug similar to ibutilide, which is not available in Japan. If the arrhythmias were not successfully terminated, internal cardioversion was performed.
Evaluation of PVI
PVP electrogram recordings using a circular catheter (Inquiry Optima, St. Jude Medical) during SR before and after CFAE-ablation were analyzed blindly offline. The electrograms were collected and measured with Prucka (GE Medical Systems, Inc., Milwaukee, WI, USA) and CARTO mapping systems. Since it was difficult to assure identical placement of the circular catheter before and after CFAE-ablation, and because the PVP could be delayed (about 5-10 ms) if the catheter position was not in the exact same place, then a difference in PVP of 30 ms or more was defined as ''delayed.''
Follow-up and outcome
Post-procedure, patients continued anticoagulation with warfarin for a minimum of 3 months. Patients were followed at 1, 3, 6, and 12 months post-ablation. A 12-lead electrocardiogram and 24-h Holter recording were done routinely in all patients at each of the follow-up visits. External loop recorders were used to confirm rhythms for any patient-reported suspicious symptoms outside of the routine follow-ups. Recurrences were based upon patient reporting, loop, Holter device, and/or electrocardiogram detection. No patients were lost to follow-up, and all underwent the required outpatient visits and monitoring.
Results
Incidence of AF termination during CFAE-ablation
AF was converted to SR in 53 (98%) patients with paroxysmal AF (16 [30%] with nifekalant), in 28 (80%) patients with persistent AF (16 [57%] with nifekalant), and in 6 (55%) patients with long-standing persistent AF (5 [83%] with nifekalant). When the AF was ''organized'' or changed to atrial tachycardia or flutter, we also ablated the points which showed more organized fractionated potential around the CFAE areas to convert to SR; we did not perform linear ablation in this study (Fig. 1 ). The remaining patients required cardioversion to maintain SR.
The common areas of the CFAE were at the anterior aspect of the right PV antrums, the posterior aspect of the left PV antrums, the ridge of the LA appendage, the proximal CS, and the posterior septum of the right atrium. The mean RF time, procedure time, and fluoroscopic time are shown in Table 2 .
PVI before and after CFAE-ablation
Internal cardioversion was attempted to convert AF to SR only once; however, SR was not maintained during the study 
Outcomes
The outcome of at least 12 months of follow-up of all patients (23 ± 5 months) was 65% of paroxysmal (11% with drug), 54% of persistent (37% with drug), and 45% of longstanding persistent AFs (60% with drug) in one session. We determined the procedure was a failure when a patient still had arrhythmias and wanted to have a second session, even if the patient had no arrhythmias with antiarrhythmic drugs, but had them without drugs. Additionally, regarding the patients who had at least one PV isolated or who had delayed PVP, 12 of 17 (71%) paroxysmal AF patients and 5 of 9 (56%) persistent AF patients were free from atrial arrhythmias, including with drug in one session. There was no difference between the patients whose PVP was effected by CFAE ablation or not (p = 0.17 in paroxysmal, p = 0.78 in persistent).
Procedure complications
There were no complications (e.g. cerebrovascular accident, high-grade atrioventricular nodal block, hemopericardium treated with pericardiocentesis, esophageal-LA fistula, clinical PV stenosis, or vascular complications at the femoral puncture site) in this study.
Outcomes compared with PVI
Even though our study was not designed to compare CFAEablation with PVI for the treatment of AF, we believe that it will give some insight into the relative efficacy and safety between these 2 strategies. Thus, we compared the current study's results with our previously performed PVI (circumferential PV antrum ablation) in our institution in 55 patients maintained after this RF application. The RF point was in the same area where we ablated the AF. Any liner ablations were not attempted to terminate AT. with paroxysmal AF and 21 with persistent AF (no patients with long-standing persistent AF had PVI). Table 3 summarizes and compares the outcomes of the 2 ablative approaches. For patients with paroxysmal AF, the outcome of the 2 strategies was similar. After 1 session, the success rate was 73% in the PVI group versus 65% in the CFAE-ablation group in the current study (p = 0.22). However, for patients with persistent AF, after 1 session, only 33% were free of AF/atrial tachyarrhythmias in the PVI group compared with 54% in the CFAE-ablation group (p < 0.01).
Discussion
Catheter ablation of AF by targeting CFAE as the sole strategy remains controversial. Nademanee et al. demonstrated that this approach is very effective at both terminating AF in the electrophysiology laboratory as well as maintaining SR; however, the same results have not been replicated in other studies to date. The findings from our study clearly confirm that CFAE-guided AF ablation is indeed as effective as PVI in patients with paroxysmal AF and is more effective in persistent AF, as described below.
Major findings
First, CFAE-ablation resulted in AF termination in a high percentage of patients in our study. AF was terminated in 98% of patients with paroxysmal AF, 80% of patients with persistent AF, and 55% of patients with long-standing AF, even though nifekalant was occasionally injected to highlight the residual CFAE sites instead of ibutilide. Second, the PVP was found to be inadvertently isolated during CFAEablation in only 8% of PVs. Third, CFAE-ablation resulted in a prolongation (>30 ms) of the interval from the local atrial potential to the PVP in 13% of PVs. Last, in 26 of 61 patients (43%), the PVP was delayed or at least one PV was isolated, and the outcome of these patients was similar to the patients whose PVP was not affected in all 4 PVs by CFAE ablation.
Although the PV was unintentionally isolated by CFAEablation in only 8% of PVs, AF was successfully terminated in virtually all patients with paroxysmal AF, and in the majority of patients with persistent and long-standing AF, without mesh image of the LA. Right panels show the intracardiac electrocardiograms before and after the AF termination caused by RF application to the LA posterior wall (yellow dot, arrow), and AF was no longer induced after this RF application. cardioversion. This study confirms the findings of Nademanee et al. [7, 16, 17] that CFAE-ablation yielded a very high rate of acute AF termination during the ablative procedure; however, these findings are different from those of other investigators, who found a very low termination rate during CFAE-ablations [6, 27] . There were some reports about the learning curve of PVI [28, 29] , but there have not been any reports about the learning curve of CFAE ablation. Then although the reasons behind the differences in the acute termination rate of the CFAE-ablation remain unknown, one must recognize that CFAEs are more challenging than PVI for several reasons. First, performing CFAE-ablation requires detailed mapping of both the atria and CS to search for CFAE target sites, whereas anatomical-based PVI is more stable because it has specific PVs as the target sites. Other complexities include the knowledge of dis-tribution of CFAE areas, the type of potential pattern that must be ablated [30] , and the fact that the sites that harbor good CFAE targets for ablation tend to have areas with a high density of CFAE points cluttering in the same location. This in turn requires several repeated RF applications over the areas juxtapositioned to the target sites in order to eliminate all CFAEs and typically results in a high density of ablation points at the target sites ( Figs. 1 and 2) . In contrast, the points ablated by electrophysiologists during CFAE-ablation in other studies looked sparse [6, 27] and appeared differently than those in our study.
In any event, our high rate of success in acute termination translates into a very good long-term outcome. After one session of AF ablation and after follow-up of a minimum of 12 months, 65% of paroxysmal AF patients, 54% of persistent AF patients, and 45% of long-standing AF patients remain free of atrial arrhythmias. Our study is comparable with that of Nademanee et al., and interestingly highlights their previous observation that the clinical outcomes after one session are as good as PVI in paroxysmal AF patients and much better in persistent AF patients. Table 4 summarizes these results [27, [31] [32] [33] [34] .
There may be concern about the use of nifekalant to highlight the residual CFAE sites, because nifekalant could terminate AF by itself. But a previous report demonstrated that the use of ibutilide was not associated with the outcome [35] and we also confirmed that in the use of nifekalant. The possible role of nifekalant is to highlight the residual CFAE sites by prolonging the cycle length and ''organizing'' the AF, and the potential of CFAE is also ''organizing'' (Fig. 1c , left bottom panel), and then the residual CFAE sites were easy to be detected.
Our observation clearly suggests that CFAE-ablation could yield very good long-term outcomes for AF patients without the need for PVI. The Heart Rhythm Society Expert Consensus Statement stated that PVI is a cornerstone of AF ablation, especially for patients with paroxysmal AF [26] . Our results clearly offer a different view point that AF could be effectively treated without having to isolate all 4 veins. However, this does not imply that PVs are not important in the pathophysiological mechanisms of AF genesis, especially in patients with paroxysmal AF. A majority of electrophysiologists may believe that the distal of the PVs are the main source of AF trigger, then PVI is mandatory. But there were only a few premature atrial contractions after CFAE ablation. Then we estimate that the areas of triggering and perpetuating of AF are similar and both show fractionated potential. We did not conclude that the PVI was not appropriate to the first line therapy for paroxysmal AF, and CFAE ablation is challenging in the beginning, but once electrophysiologists get used to CFAE ablation, they do not have to struggle to decide the strategies of AF ablation even in the patients with structural heart disease, large LA volume, and those who have a history of PVI and/or persistent/longstanding AF.
Chen et al. reported that during PVI, extending the ablation lesions by up to 10 mm from the PV ostia might cover most high-frequency CFAEs around the PV antrums, and that high-frequency CFAEs were more often located in the PV ostia in patients with paroxysmal AF than in patients with persistent AF [36] . In this study, CFAE-ablation resulted in a prolongation (>30 ms) of the interval from the local atrial potential to the PVP in 13% of PVs. In 26 of 61 (43%) patients, the interval from the local atrial potential to the PVP was prolonged or at least 1 of the 4 PVs was isolated.
These results correspond with those reported by Chen et al. [36] . The areas around PVs are relatively more important in the underlying electrophysiologic mechanism of paroxysmal AF compared to that of persistent AF. The distribution of CFAE areas included the anterior aspect of the right PVs, the posterior aspect of the left PVs, and the ridge of the LA appendage [7, 30] . The ridge of the LA appendage includes the area between the left superior PV and the LA appendage. As this area is usually ablated during PVI, it is possible that the PVI may unintentionally ablate the CFAE areas, which may be why PVI eliminated AF in some patients.
Consequently, the outcome of PVI is similar to that of the CFAE-ablation in paroxysmal AF, despite the large difference in the outcome of persistent AF. We speculate that these findings may explain why additional CFAE-ablation after PVI might not improve the success rate compared with PVI alone [19] .
Although our outcomes for both acute termination and long-term maintenance of SR in paroxysmal AF patients are comparable to those of Nademanee et al., the outcome of this study in patients with persistent and long-standing AF was not as positive as previous reports [7, 16, 17, 30] . The reasons we speculate are as follows: (1) the cases in the present study were the ''initial'' 100 cases of 6 doctors who had some experience with PVI, but not with CFAE-ablation;
(2) we could only terminate AF in 55% of patients with long-standing AF; and (3) to avoid complications (cerebral infarction), at that time the maximum power was 35 W in the 3.5-mm ThermoCool NaviStar catheter, and 50 W in the 8-mm NaviStar catheter to avoid char formation.
The outcome of PVI previously performed in our institute was 73% in paroxysmal AF and 33% in persistent AF patients in one session to be adjusted the following period, even though the patient characteristics were less severe than those in the CFAE group.
Although this was not a double-blind study, the clinical outcome after one session was as good as in paroxysmal and much better than persistent AF with CFAE-ablation compared to PVI. According to this study, PVI, especially for all 4 veins, did not appear to be mandatory. Combined therapy of PVI and CFAE could yield a better outcome, even though there would be a longer procedure and fluoroscopic time using the same operators.
Verma et al. [37] reported that the outcome of combined therapy improved compared with PVI, but others reported that there was no difference [38, 39] . These patients had different backgrounds, so we could not compare these studies directly, but the former reported a better termination rate than the latter study. According to these studies, a high rate of termination may guarantee a good outcome even in combined therapy.
Study limitations
Analysis required exclusion of 39% of the patients in which SR could not be maintained before ablation and/or in which PVP of all 4 veins was absent due to previous PVI(s). It was difficult to maintain SR during recording of the PVP before CFAE-ablation, especially in patients with persistent/longstanding AF, because movement of the circular catheter often triggered re-initiation of AF. PVs might be more likely to be inadvertently isolated by CFAE-ablation in patients with persistent AF than paroxysmal AF because there are more RF points in ablation for patients with persistent AF than paroxysmal AF.
However, there was not a big difference between the two groups; the number of the patients who had at least one PV isolated or delayed PVP was 17 of 42 (40%) in paroxysmal and 9 of 19 (47%) in persistent AF. And the outcome of the patients with at least one PV isolated or delayed PVP was similar to the patients whose PVP was not affected in all 4 PVs by CFAE ablation. Therefore, even though no PVP information was available from the remaining 39 excluded patients, this should not significantly bias the results.
Conclusions
Our data demonstrate that areas which consistently harbor CFAE are important in maintaining AF, and show that the strategy of ablating such areas is an effective approach in terminating AF and maintaining SR without the need to isolate all 4 PVs. Our study findings undoubtedly will be controversial, but hopefully will lead to further studies that will provide an AF ablative approach, which will yield the best clinical outcomes and lowest procedural risks.
